The increase in proportion of patients with IgM <0.4 g/L following rituximab, is consistent with previous data in SLE and AAV patients [3,20-23,26]. This evidence concerns the gene CD40LG and anti-neutrophil cytoplasmic antibody-associated vasculitis.